A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents

Bone Marrow Transplantation

Volumn 46, Issue 6, 2011, Pages 790-799

  Styczynski, J ^a,b   Tallamy, B ^b   Waxman, I ^b   Van De Ven, C ^b   Milone, M C ^c   Shaw, L M ^c   Harrison, L ^b   Morris, E ^b   Satwani, P ^b   Bhatia, M ^b   George, D ^b   Bradley, M B ^b   Garvin, J H ^b   Schwartz, J ^d   Baxter Lowe, L A ^e   Cairo, M S ^b,d  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AlloHSCT; pediatric; reduced toxicity conditioning

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BUSULFAN; CD19 ANTIGEN; CIDOFOVIR; COTRIMOXAZOLE; DIPHENHYDRAMINE; ETIRACETAM; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PENTAMIDINE; PHENYTOIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CANCER SURVIVAL; CD34 SELECTION; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG CLEARANCE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATURIA; HERPES SIMPLEX; HLA MATCHING; HLA TYPING; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; NEUROBLASTOMA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PILOT STUDY; PNEUMOCYSTOSIS; PREMEDICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SCLERODERMA; SEIZURE; STEADY STATE; SURVIVAL TIME; T CELL LEUKEMIA; VIRUS INFECTION; WOLMAN DISEASE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PILOT PROJECTS; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; YOUNG ADULT;

EID: 79958089426     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.209     Document Type: Article

References (33)

1. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 523-536.
2. Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 2005; 11: 403-422. (Pubitemid 40753793)
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763. (Pubitemid 28078275)
4. Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid Bradley M, George D et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613-622. (Pubitemid 38455923)
5. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162. (Pubitemid 38891687)
6. Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity conditioning for allogeneic hematopoeitic cell transplantation: current perspectives. Biol Blood Marrow Transplant 2009; 13(suppl 1): 87-97. (Pubitemid 46044111)
7. Satwani P, Morris E, Bradley MB, Bhatia M, van de Ven C, Cairo MS. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 2008; 50: 1-8. (Pubitemid 350234257)
8. Lim ZY, Ingram W, Brand R, Akthari M, Milojkovic D, Ho AY et al. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. Bone Marrow Transplant 2007; 40: 747-752. (Pubitemid 47521534)
9. Horn B, Baxter-Lowe LA, Englert L, McMillan A, Quinn M, Desantes K et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006; 37: 263-269.
10. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using .udarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623. (Pubitemid 39202266)
11. Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007; 40: 621-631. (Pubitemid 47456476)
12. Bullock JM, Smith PF, Booker BM, Loughner J, Capozzi D, McCarthy Jr PL et al. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 2006; 28: 62-66. (Pubitemid 44391695)
13. Fraser JK, Cairo MS, Wagner EL, McCurdy PR, Baxter-Lowe LA, Carter SL et al. Cord Blood Transplantation Study (COBLT): cord blood bank standard operating procedures. J Hematother 1998; 7: 521-561.
14. Kurtzberg J, Cairo MS, Fraser JK, Baxter-Lowe L, Cohen G, Carter SL et al. Results of the cord blood transplantation (COBLT) study unrelated donor banking program. Transfusion 2005; 45: 842-855. (Pubitemid 40798774)
15. Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995; 92: 10119-10122.
16. Kasow KA, Sims-Poston L, Eldridge P, Hale GA. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients. Biol Blood Marrow Transplant 2007; 13: 608-614. (Pubitemid 46585932)
17. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10: 246-258. (Pubitemid 38456203)
18. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
19. Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E et al. Sequential administration of sargramostim and .lgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. Pediatr Transplant 2009; 13: 464-474.
20. Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 325-330.
21. Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 2007; 49: 306-312. (Pubitemid 47236221)
22. Horn B, Soni S, Khan S, Petrovic A, Breslin N, Cowan M et al. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant 2009; 43: 469-476.
23. Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R et al. Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1022-1030. (Pubitemid 47215557)
24. Kaplan EL, Meier P. Non parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant; 2010; 16: 333-343.
26. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992-5001.
27. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11: 383-392.
28. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757-770.
29. Kalwak K, Gorczynska E, Toporski J, Turkiewicz D, Slociak M, Ussowicz M et al. Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery. Br J Haematol 2002; 118: 74-89. (Pubitemid 34779519)
30. Small TN. Immunologic reconstitution following stem cell transplantation. Curr Opin Hematol 1996; 3: 461-465.
31. Shah AJ, Kapoor N, Crooks GM, Weinberg KI, Azim HA, Killen R et al. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants. Biol Blood Marrow Transplant 2007; 13: 584-593.
32. Koehl U, Bochennek K, Zimmermann SY, Lehrnbecher T, Sorensen J, Esser R et al. Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+ CD3+ count reconstitution is associated with survival. Bone Marrow Transplant 2007; 39: 269-278. (Pubitemid 46322633)
33. Schwinger W, Weber-Mzell D, Zois B, Rojacher T, Benesch M, Lackner H et al. Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children. Br J Haematol 2006; 135: 76-84. (Pubitemid 44337666)